XENE Q4 2021 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-27.4% YoY

Gross Profit

-$18M-485.7% margin

Operating Income

-$25M-664.7% margin

Net Income

-$26M-684.1% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

-54.0%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$572M

Total Liabilities

$22M

Stockholders' Equity

$550M

Cash & Equivalents

$176M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-27.4%
Gross Profit	-$18M	-$10M	-84.9%
Operating Income	-$25M	-$13M	-92.2%
Net Income	-$26M	-$12M	-107.4%

Revenue Segments

License And Service

$9M100%